Page 64 - Read Online

Page 18 of 18 Galicia-Moreno et al. Hepatoma Res 2020;6:20 I http://dx.doi.org/10.20517/2394-5079.2019.36

94. Leathers JS, Balderramo D, Prieto J, Diehl F, Gonzalez-Ballerga E, et al. Sorafenib for treatment of hepatocellular carcinoma: a
survival analysis from the south american liver research network. J Clin Gastroenterol 2019;53:464-9.
95. Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterol
2019;156:510-24.
96. De Mattia E, Cecchin E, Guardascione M, Foltran L, Raimo TD, et al. Pharmacogenetics of the systemic treatment in advanced
hepatocellular carcinoma. World J Gastroenterol 2019;25:3870-96.
97. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
98. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
99. Turkes F, Chau I. Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future Oncol 2019;15:979-88.
100. Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther
2018;18:1169-75.
101. Wang J, Ma L, Tang X, Zhang X, Qiao Y, et al. Doxorubicin induces apoptosis by targeting Madcam 1 and AKT and inhibiting protein
translation initiation in hepatocellular carcinoma cells. Oncotarget 2015;6:24075-91.
102. Zhou Y, Li K, Li F, Han S, Wang Y, et al. Doxorubicin and ABT-199 coencapsulated nanocarriers for targeted delivery and synergistic
treatment against hepatocellular carcinoma. J Nanomat 2019;2019:13.
103. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-
analysis. PloS One 2013;8:e61361.
104. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther
2012;135:44-53.
105. Nishiguchi S, Kuroti T, Nakatani S, Morimoto H, Takeda T, et al. Randomised trial of effects of interferon-alpha on incidence of
hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
106. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnú L, et al. Sustained virological response to interferon-alpha is associated with
improved outcome in HVC-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
107. Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining
challenges. Gastroenterology 2019;156:431-45.
108. Piñero F, Boin I, Chagas A, Quiñonez E, Marciano S, et al. Direct-acting antivirals and hepatocellular carcinoma: no evidence of
higher waitlist progression or post-transplant recurrence. Liver Transpl 2020; epub ahead of print. doi: 10.1002/lt.25744
109. Mendizabal M, Piñero F, Ridruejo E, Wolff FH, Anders M, et al. Disease progression in patients with hepatitis C virus infection
treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2020;28:30263-9.